<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
<channel>
  <title>NewswireToday - Free Press Release - Free Newswire Distribution - Pharma/BioTech/Nutrition</title>
  <link>http://www.newswiretoday.com/</link>
  <description>Recent Pharma/BioTech/Nutrition NewswireToday - PRZOOM Headline News - Visit PressReleasesNewswireDistribution.com</description>
  <pubDate>Fri, 03 Feb 2012 22:13:28 -0500</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
 <generator>rss20 by http://www.newswiretoday.com/</generator>
 <webMaster>newsfeed_888@newswiretoday.com</webMaster>

<item>
  <title>European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products Says Frost &amp; Sullivan</title>
  <description>NewswireToday (newswire) - 02/01/2012 London,  United Kingdom - Increasing incidence of thrombosis, paralleled by maturing life cycles of existing products, underpin the demand for novel alternatives - Pharma.Frost.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105224/</link>
  <pubDate>02/01/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>Rising Interest of Big Pharma Creates Immense Growth Potential for Contract Manufacturing Organisations Says Frost &amp; Sullivan</title>
  <description>NewswireToday (newswire) - 01/23/2012 London,  United Kingdom - Technical expertise, potential for time and cost savings underlines viability of contract outsourcing - Pharma.Frost.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/104572/</link>
  <pubDate>01/23/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>Rapidly Evolving Stem Cells Market Opens Up Doors for Related Research Tools Says Frost &amp; Sullivan</title>
  <description>NewswireToday (newswire) - 01/20/2012 London,  United Kingdom - Lack of venture capital infusions threatens to slow pace of research and market development - Drugdiscovery.Frost.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/104474/</link>
  <pubDate>01/20/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>The NAPRX CNPR Certification Program Earns E-Learning Award from the PRMA Institute</title>
  <description>NewswireToday (newswire) - 02/03/2012 Washington, DC United States - The real power of the NAPRX CNPR Certification is that sales professionals learn to communicate with physicians. The NAPRX CNPR certification was recognized for the award after a rigorous evaluation of the NAPRX CNPR course’s usability and design</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105415/</link>
  <pubDate>02/03/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>Bioptigen Envisu SDOCT Used in Rare Elephant Cataract Surgery</title>
  <description>NewswireToday (newswire) - 02/02/2012 Raleigh, NC United States - Surgery also marked first time SDOCT used to image elephant - Bioptigen.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105338/</link>
  <pubDate>02/02/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>Wyatt Technology Employed to Develop Alternative Materials to Faulty Silicone Breast Implants</title>
  <description>NewswireToday (newswire) - 02/01/2012 Santa Barbara, CA United States - Wyatt Technology Corporation, announced that Professor Judit E. Puskas at the University of Akron has developed a system using its instrumentation that will also help to solve a prevalent and particularly controversial material science challenge</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105210/</link>
  <pubDate>02/01/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>Frost &amp; Sullivan Acclaims Corden Pharma for Achieving Excellence in Product Differentiation</title>
  <description>NewswireToday (newswire) - 02/01/2012 London,  United Kingdom - Unique product mix and technical excellence distinguish Corden Pharma from the competition - CordenPharma.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105217/</link>
  <pubDate>02/01/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>AnaSpec Announces Antibodies Against the Hexa-His and GFP Tags</title>
  <description>NewswireToday (newswire) - 02/01/2012 Fremont, CA United States - AnaSpec, EGT Group is pleased to offer a wide selection of high quality monoclonal and polyclonal antibodies against the hexa-His and GFP tags - Anaspec.com / Eurogentec.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105245/</link>
  <pubDate>02/01/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>inGenious Targeting Laboratory, Inc. Announces New Headqueaters</title>
  <description>NewswireToday (newswire) - 01/31/2012 Ronkonkoma, NY United States - inGenious Targeting Laboratory's larger, state-of-the-art headquarters will provide provide iTL with new opportunities as iTL continues to define itself as a leader in the custom mouse model industry - Genetargeting.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105072/</link>
  <pubDate>01/31/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>Synowledge Announces Record Growth in 2011 – Anticipates Sustained Progress in 2012</title>
  <description>NewswireToday (newswire) - 01/31/2012 Stamford, CT United States - Synowledge is a global provider of drug safety, regulatory affairs and related IT solutions to small, mid and large sized pharmaceutical and biotechnology companies - Synowledge.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105087/</link>
  <pubDate>01/31/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>Bio-Synthesis Expands Proteomic Platform with Enhanced Peptide Tools</title>
  <description>NewswireToday (newswire) - 01/31/2012 Lewisville, TX United States - Bio-Synthesis has added multiple peptide tools that can help researchers design their project and receive immediate feedback based on specific parameters - BioSyn.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105139/</link>
  <pubDate>01/31/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>TCGLS Completes Key Milestones on Delivery of Pre-clinical Drug Candidates to Endo Pharma</title>
  <description>NewswireToday (newswire) - 01/30/2012 Kolkata, West Bengal India - TCG Lifesciences Limited (TCGLS) announced the achievement of two distinct milestones in their ongoing drug discovery partnership with Endo Pharmaceuticals. TCGLS will receive undisclosed success fees against these milestones - TCGLS.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/104978/</link>
  <pubDate>01/30/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>AnaSpec Introduces SensoLyte® Factor Xa Activity Assays - Industry’s First Fluorimetric Kits</title>
  <description>NewswireToday (newswire) - 01/30/2012 Fremont, CA United States - AnaSpec, EGT Group is pleased to announce the release of the industry first fluorimetric Factor Xa activity assays - The SensoLyte® 520 Factor Xa Assay Kit and the SensoLyte® Rh110 Factor Xa Assay Kit - Anaspec.com / Eurogentec.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105033/</link>
  <pubDate>01/30/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>BTG Announces Positive Data from First US Phase III Trial of Varisolve®</title>
  <description>NewswireToday (newswire) - 01/30/2012 London,  United Kingdom - Study meets all primary, secondary and tertiary endpoints (LSE: BGC) - BTCplc.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105062/</link>
  <pubDate>01/30/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

<item>
  <title>FDA Approves Erivedge (Vismodegib) Capsule, the First Medicine for Adults with Advanced Basal Cell Carcinoma</title>
  <description>NewswireToday (newswire) - 01/30/2012 South San Francisco, CA United States - Erivedge is a first-in-class hedgehog pathway inhibitor that helps shrink disfiguring or potentially life-threatening lesions in advanced skin cancer (SIX: RO, ROG; OTCQX: RHHBY) - RocheTrials.com / gene.com</description>
  <imgUrl>images/nophoto.gif</imgUrl>
  <link>http://www.newswiretoday.com/news/105066/</link>
  <pubDate>01/30/2012</pubDate>
  <category>Pharma/BioTech/Nutrition</category>
</item>

</channel>
</rss>
